Bladder Cancer Gene Therapy Adstiladrin Offers New Option in Slim Category
-
Apr 13, 2023
In late 2022, the FDA approved the first gene therapy for bladder cancer, Ferring Pharmaceuticals’ Adstiladrin (nadofaragene firadenovec-vncg). Almost three-quarters of oncologists surveyed by Zitter Insights expressed at least moderate interest in the agent, and payers said they expect to manage the drug to label. While the drug gives another treatment alternative to a much-needed area, it likely will continue to put financial pressure on payers, industry experts tell AIS Health, a division of MMIT.
On Dec. 16, the FDA approved Adstiladrin for the treatment of adults with high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. The agency gave the novel adenovirus vector-based gene therapy priority review, breakthrough therapy and fast track designations. Dosing is once every three months into the bladder via a urinary catheter. The company said it expects the therapy to be available in the second half of 2023.
Read more
© 2024 MMIT
Related Posts
-
![]()
Mar 09
Gilead’s First-in-Class HIV Drug Sunlenca Offers Much-Needed Option
Read more -
![]()
Feb 09
FDA Approves Hemophilia B Gene Therapy, but Its Cost May Pose Access Problems for Payers
Read more -
![]()
Nov 10
Oncologists May Prescribe New Neutropenia Agent Over Others in Class, but Therapy Faces Another Challenge
Read more
The Latest
Meet Our Reporters
Meet Our Reporters
GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND
Sign up for publications to get unmatched business intelligence delivered to your inbox.